Fusions involving FGFR3 and TACC3 (transforming acidic coiled-coil containing protein 3) are found in 3% to 7% of glioblastomas,3%to6%of urothelial bladder carcinomas, and other tumor types at lower frequencies. In mouse xenograft models, the induction of FGFR3--TACC3 expression in human astrocytes resulted in the development of gliomalike tumors. In vivo, both FGFR3–TACC3–initiated bladder carcinoma and glioblastoma were extremely sensitive to specific FGFR inhibitors, suggesting oncogenic addiction to the fusion protein.
Drug targets for cancer: FGFR3 research reagents
Other vital drug targets for cancer likeFGFR3:
Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer[J]. Clinical Cancer Research, 2015, 21(12): 2684-2694.